- Published at
- by insidermonkey.com
negative
negative
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil
We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil.
News for Nektar Therapeutics (0UNL.L)
- Published at
- by seekingalpha.com
positivepositiveNektar stock upgraded at Oppenheimer (NKTR:NASDAQ)
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read more here.- Published at
- by zacks.com
negativenegativeNektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by gurufocus.com
neutralneutralNektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cash and Investments: $269.1 million at the end of 2024.Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024.R&D Expenses: $28.7 million fo- Published at
- by gurufocus.com
positivepositiveQ4 2024 Nektar Therapeutics Earnings Call Transcript
Mar 12, 2025 / 09:00PM GMTOperator Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference c- Published at
- by zacks.com
neutralneutralNektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by gurufocus.com
positivepositiveNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireSAN FRANCISCO, March 12, 2025 SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results- Published at
- by gurufocus.com
mixedmixedMBX Biosciences Announces Additions to Leadership Team
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Qualit- Published at
- by gurufocus.com
neutralneutralNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
PR NewswireSAN FRANCISCO, Feb. 26, 2025 SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com- Published at
- by gurufocus.com
positivepositiveNektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
PR NewswireSAN FRANCISCO and NEW YORK, Feb. 24, 2025 -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --SAN FRANCISCO and N- Published at
- by gurufocus.com
positivepositiveSamlyn Capital, LLC Increases Stake in Nektar Therapeutics
On December 31, 2024, Samlyn Capital, LLC executed a notable transaction by acquiring an additional 467,097 shares of Nektar Therapeutics at a trade price of $0- Published at
- by gurufocus.com
positivepositiveEventide Asset Management, LLC Reduces Stake in Nektar Therapeutics
Eventide Asset Management, LLC, a well-regarded investment firm, recently made a significant adjustment to its holdings in Nektar Therapeutics. On December 31,- Published at
- by gurufocus.com
positivepositiveDeep Track Capital, LP Reduces Stake in Nektar Therapeutics
On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings- Published at
- by gurufocus.com
neutralneutralNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
PR NewswireSAN FRANCISCO, Feb. 10, 2025 SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food- Published at
- by rttnews.com
positivepositiveNektar Therapeutics Gets Fast Track Designation For Rezpegaldesleukin In Atopic Dermatitis; Stock Up
Nektar Therapeutics (NKTR) Monday said that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for its drug candidate rezpegaldesleukin for the treatment of atopic dermatitis in patients aged 12 years and older.- Published at
- by gurufocus.com
mixedmixedNektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volatility
Nektar Therapeutics (NKTR) experienced a significant stock price drop of 5.02%, trading at $0.666 per share with a trading volume of 1.89413 million shares. The- Published at
- by gurufocus.com
positivepositiveNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
PR NewswireSAN FRANCISCO, Jan. 10, 2025 SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com- Published at
- by gurufocus.com
mixedmixedArvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
”“ Vepdegestrant to be combined with Pfizer's novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a se- Published at
- by manilatimes.net
mixedmixed- Published at
- by insidermonkey.com
positivepositiveWhy Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media?
We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media.